Thomas D Norton, Mazhar Thakur, Samit Ganguly, Shazia Ali, Jesse Chao, Alpana Waldron, Jing Xiao, Kenneth C Turner, John D Davis, Susan C Irvin, Cynthia Pan, Dominique Atmodjo, Andrea T Hooper, Jennifer D Hamilton, Mohamed Hussein, Danise Subramaniam, Lilia Roque-Guerrero, Anita Kohli, Eleftherios Mylonakis, Gregory P Geba, Edward Cox, Ned Braunstein, Paula Dakin, Bari Kowal, Rafia Bhore, A Thomas DiCioccio, Diana Hughes, Gary A Herman
{"title":"卡西利韦单抗和伊马单抗(CAS+IMD)在COVID-19儿科门诊患者中的安全性和药代动力学。","authors":"Thomas D Norton, Mazhar Thakur, Samit Ganguly, Shazia Ali, Jesse Chao, Alpana Waldron, Jing Xiao, Kenneth C Turner, John D Davis, Susan C Irvin, Cynthia Pan, Dominique Atmodjo, Andrea T Hooper, Jennifer D Hamilton, Mohamed Hussein, Danise Subramaniam, Lilia Roque-Guerrero, Anita Kohli, Eleftherios Mylonakis, Gregory P Geba, Edward Cox, Ned Braunstein, Paula Dakin, Bari Kowal, Rafia Bhore, A Thomas DiCioccio, Diana Hughes, Gary A Herman","doi":"10.1093/jpids/piae105","DOIUrl":null,"url":null,"abstract":"<p><p>The safety of casirivimab+imdevimab (CAS+IMD) (anti-SARS-CoV-2 monoclonal antibodies [mAbs]) in pediatric outpatients with COVID-19 was evaluated in a randomized, phase 1/2/3 trial. Consistent with adults, CAS+IMD was generally well tolerated with low drug-induced immunogenicity rates. The findings support development of next-generation anti-SARS-CoV-2 mAbs for at-risk pediatric patients.</p>","PeriodicalId":17374,"journal":{"name":"Journal of the Pediatric Infectious Diseases Society","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Safety and Pharmacokinetics of Casirivimab and Imdevimab (CAS+IMD) in Pediatric Outpatients With COVID-19.\",\"authors\":\"Thomas D Norton, Mazhar Thakur, Samit Ganguly, Shazia Ali, Jesse Chao, Alpana Waldron, Jing Xiao, Kenneth C Turner, John D Davis, Susan C Irvin, Cynthia Pan, Dominique Atmodjo, Andrea T Hooper, Jennifer D Hamilton, Mohamed Hussein, Danise Subramaniam, Lilia Roque-Guerrero, Anita Kohli, Eleftherios Mylonakis, Gregory P Geba, Edward Cox, Ned Braunstein, Paula Dakin, Bari Kowal, Rafia Bhore, A Thomas DiCioccio, Diana Hughes, Gary A Herman\",\"doi\":\"10.1093/jpids/piae105\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The safety of casirivimab+imdevimab (CAS+IMD) (anti-SARS-CoV-2 monoclonal antibodies [mAbs]) in pediatric outpatients with COVID-19 was evaluated in a randomized, phase 1/2/3 trial. Consistent with adults, CAS+IMD was generally well tolerated with low drug-induced immunogenicity rates. The findings support development of next-generation anti-SARS-CoV-2 mAbs for at-risk pediatric patients.</p>\",\"PeriodicalId\":17374,\"journal\":{\"name\":\"Journal of the Pediatric Infectious Diseases Society\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the Pediatric Infectious Diseases Society\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/jpids/piae105\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Pediatric Infectious Diseases Society","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/jpids/piae105","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Safety and Pharmacokinetics of Casirivimab and Imdevimab (CAS+IMD) in Pediatric Outpatients With COVID-19.
The safety of casirivimab+imdevimab (CAS+IMD) (anti-SARS-CoV-2 monoclonal antibodies [mAbs]) in pediatric outpatients with COVID-19 was evaluated in a randomized, phase 1/2/3 trial. Consistent with adults, CAS+IMD was generally well tolerated with low drug-induced immunogenicity rates. The findings support development of next-generation anti-SARS-CoV-2 mAbs for at-risk pediatric patients.
期刊介绍:
The Journal of the Pediatric Infectious Diseases Society (JPIDS), the official journal of the Pediatric Infectious Diseases Society, is dedicated to perinatal, childhood, and adolescent infectious diseases.
The journal is a high-quality source of original research articles, clinical trial reports, guidelines, and topical reviews, with particular attention to the interests and needs of the global pediatric infectious diseases communities.